References
- Ebers GC. Treatment of multiple sclerosis. Lancet343, 275–278 (2004).
- Kurtzke JF. MS epidemiology world wide. One view of current status. Acta Neurol. Scand. Suppl.161, 23–33 (1995).
- Behan PO. Acute disseminated encephalomyelitis: postinfectious, postimmunization and variant forms. Expert Rev. Neurother.9(9), 1321–1329 (2009).
- Behan PO, Chaudhuri A, Roep BO. The pathogenesis of multiple sclerosis revisited. J. R. Coll. Physicians (Edinb.)32, 244–265 (2002).
- Greve B, Simonenko R, Illes Z et al. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Mult. Scler.14, 153–158 (2008).
- Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol.58(6), 939–945 (2005).
- Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med.358, 676–688 (2008).
- Quinn S. Human Trials: Scientists, Investors and Patients in the Quest for a Cure. Perseus Publishing, Cambridge, MA, USA (2001).
- Steiner I, Wirguin I. Multiple sclerosis – in need of a critical reappraisal. Med. Hyopthese54(1), 99–106 (2000).
- Rice GP, Incorvia B, Munari L et al. Interferon in relapsing–remitting multiple sclerosis Cochrane Database Syst. Rev.4, CD002002 (2001).
- The CAMMS223 Trial Investigators. Alemtuzumab vs interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359, 1786–1801 (2008).
- Lindå H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med.361(11), 1081–1087 (2009).
- Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J. Neurol.256(10), 1771–1772 (2009).
- Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult. Scler.15(12), 1532–1533 (2009).
- Warwar RE, Bullock JD, Shields JA, Eagle RC. Coexistence of three tumours of neural crest origin. Arch. Opthalmol.116, 1241–1243 (1998).
- Carroll WM. Oral therapy for multiple sclerosis – sea change or incremental step? N. Engl. J. Med.362(5), 456–458 (2010).
- Wiendl W, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology17, 1008–1015 (2009).
- Dhib-Jalput S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology58(Suppl. 4), S3–S9 (2002).
- Gulcher JR, Vartanian T, Stefansson K. Is multiple sclerosis an autoimmune disease? Clin. Neurosci.2(3–4), 246–252 (1994).
- Vandenbroeck K, Comabella M, Tolosa E et al. United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics10(5), 885–894 (2009).
- Woodhoo A, Alonso MB, Droggiti A et al. Notch controls embryonic Schwann cell differentiation, postnatal myelination and adult plasticity. Nat. Neurosci.12(7), 839–847 (2009).
- Wang Y, Wu C, Caprariello AV et al.In vivo quantification of myelin changes in the vertebrate nervous system. J. Neurosci.29(46), 14663–14669 (2009).
- Behan PO, Chaudhuri A. The sad plight of multiple sclerosis research: low in fact, high in fiction. Eur. Neurol. Rev. (2010) (In press).
- Frank JA, Richert N, Lewis B et al. A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients. Mult. Scler.8, 24–29 (2002).
Websites
- NIH: clinical trials http://clinicaltrials.gov
- Clinical trials in multiple sclerosis http://clinicaltrials.gov/ct2/results?term=%22multiple+sclerosis%22 (Accessed 25 November 2009)
- Open multiple sclerosis drug studies Link (Accessed 25 November 2009)
- BIOMS press release www.biomsmedical.com/display-press-release.php?id=198 (Accessed 28 September 2009)